LeMaitre Vascular (NASDAQ:LMAT) Downgraded to Hold at StockNews.com

StockNews.com downgraded shares of LeMaitre Vascular (NASDAQ:LMAT) from a buy rating to a hold rating in a report published on Friday.

Other analysts have also issued research reports about the company. Roth Capital raised LeMaitre Vascular to a strong-buy rating in a research report on Friday, May 31st. Stifel Nicolaus raised LeMaitre Vascular from a hold rating to a buy rating and upped their price objective for the stock from $59.00 to $75.00 in a research report on Friday, April 26th. Lake Street Capital began coverage on LeMaitre Vascular in a report on Friday. They issued a buy rating and a $105.00 target price on the stock. Barrington Research increased their target price on LeMaitre Vascular from $79.00 to $92.00 and gave the company an outperform rating in a report on Friday. Finally, JMP Securities increased their target price on LeMaitre Vascular from $72.00 to $77.00 and gave the company a market outperform rating in a report on Friday, May 3rd. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of Moderate Buy and a consensus price target of $83.71.

LeMaitre Vascular Stock Down 1.4 %

NASDAQ:LMAT opened at $85.01 on Friday. The stock’s fifty day moving average is $82.69 and its two-hundred day moving average is $71.68. LeMaitre Vascular has a 52 week low of $44.27 and a 52 week high of $91.76. The stock has a market capitalization of $1.91 billion, a price-to-earnings ratio of 56.30, a price-to-earnings-growth ratio of 2.63 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. LeMaitre Vascular had a return on equity of 12.63% and a net margin of 18.33%. The business had revenue of $55.85 million for the quarter, compared to analyst estimates of $54.98 million. During the same quarter in the prior year, the company earned $0.37 earnings per share. The company’s revenue was up 11.4% on a year-over-year basis. On average, sell-side analysts expect that LeMaitre Vascular will post 1.77 EPS for the current fiscal year.

Insider Transactions at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 27,030 shares of LeMaitre Vascular stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the sale, the chief executive officer now owns 1,958,328 shares in the company, valued at $168,944,956.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO George W. Lemaitre sold 27,030 shares of LeMaitre Vascular stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the sale, the chief executive officer now owns 1,958,328 shares in the company, valued at $168,944,956.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO George W. Lemaitre sold 12,976 shares of the firm’s stock in a transaction dated Friday, July 12th. The stock was sold at an average price of $86.07, for a total value of $1,116,844.32. Following the transaction, the chief executive officer now directly owns 1,985,358 shares in the company, valued at approximately $170,879,763.06. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 127,437 shares of company stock worth $10,076,242. Corporate insiders own 10.79% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

A number of hedge funds and other institutional investors have recently made changes to their positions in LMAT. YHB Investment Advisors Inc. purchased a new position in shares of LeMaitre Vascular during the first quarter worth about $36,000. SRS Capital Advisors Inc. grew its holdings in shares of LeMaitre Vascular by 325.5% during the fourth quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier’s stock worth $39,000 after buying an additional 524 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of LeMaitre Vascular by 57.0% during the second quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after buying an additional 199 shares during the last quarter. West Oak Capital LLC purchased a new position in shares of LeMaitre Vascular during the second quarter worth about $58,000. Finally, nVerses Capital LLC boosted its holdings in LeMaitre Vascular by 33.3% in the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock valued at $66,000 after purchasing an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.